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Abstract
Background: Hypoglycemia is associated with increased mortality in critically ill patients. The impact of
hypoglycemia on resource utilization has not been investigated. The objective of this investigation was to evaluate
the association of hypoglycemia, defined as a blood glucose concentration (BG) < 70 mg/dL, and intensive care
unit (ICU) length of stay (LOS) in three different cohorts of critically ill patients.
Methods: This is a retrospective investigation of prospectively collected data, including patients from two large
observational cohorts: 3,263 patients admitted to Stamford Hospital (ST) and 2,063 patients admitted to three
institutions in The Netherlands (NL) as well as 914 patients from the GLUCONTROL trial (GL), a multicenter
prospective randomized controlled trial of intensive insulin therapy.
Results: Patients with hypoglycemia were more likely to be diabetic, had higher APACHE II scores, and higher
mortality than did patients without hypoglycemia. Patients with hypoglycemia had longer ICU LOS (median
[interquartile range]) in ST (3.0 [1.4-7.1] vs. 1.2 [0.8-2.3] days, P < 0.0001), NL (5.2 [2.6-10.3] vs. 2.0 [1.3-3.2] days, P <
0.0001), and GL (9 [5-17] vs. 5 [3-9] days, P < 0.0001). For the entire cohort of 6,240 patients ICU LOS was 1.8 (1.0-
3.3) days for those without hypoglycemia and 3.0 (1.5-6.7) days for those with a single episode of hypoglycemia (P
< 0.0001). This was a consistent finding even when patients were stratified by severity of illness or survivor status.
There was a strong positive correlation between the number of episodes of hypoglycemia and ICU LOS among all
three cohorts.
Conclusions: This multicenter international investigation demonstrated that hypoglycemia was consistently
associated with significantly higher ICU LOS in heterogeneous cohorts of critically ill patients, independently of
severity of illness and survivor status. More effective methods to prevent hypoglycemia in these patients may
positively impact their cost of care.
Keywords: hypoglycemia, intensive care unit, length of stay, resource utilization, APACHE II, mortality, intensive
insulin therapy
Introduction
Hyperglycemia occurs commonly in critically ill patients
and is strongly associated with increased risk of mortal-
ity [1-3]. During the past decade, a number of interven-
tional trials have assessed the impact of intensive insulin
therapy (IIT) to correct even moderate degrees of hyper-
glycemia; several have resulted in improvements in mor-
tality and/or morbidity [4-6], whereas a number did not
demonstrate benefit [7-11]. Hypoglycemia, either spon-
taneous or occurring as a complication of IIT, is a fre-
quent occurrence in critically ill patients and is
independently associated with increased risk of mortality
[12-15]. Whereas severe hypoglycemia, usually defined
as blood glucose level (BG) < 40 mg/dL, has been the
focus of most of these studies [9,12-16], other investiga-
tors have demonstrated a deleterious impact of even
mild hypoglycemia–BG < 70 mg/dL–on survival in het-
erogeneous populations of critically ill patients [17,18].
The cost of treating intensive care unit (ICU) patients
is enormous. It has been estimated that 0.5-1.0% of the
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the ICU, representing 20-30% of a typical hospital’s
costs [19,20]. A limited body of literature has explored
the impact of glycemic management protocols on the
cost of care in ICU populations [21-24]. These data sug-
gest that significant cost savings accrue from ameliora-
tion of hyperglycemia in the critically ill, associated with
reductions in ICU length of stay (LOS), ICU acquired
infections, and decreases in pharmacy, laboratory, and
diagnostic imaging use. To date, however, no studies
have investigated the impact of hypoglycemia on the
cost of care of critically ill patients.
The purpose of this study was to evaluate the impact
of hypoglycemia, defined as BG < 70 mg/dL, on
resource utilization in the ICU. The choice of a thresh-
old value of 70 mg/dL was based on several factors.
Cryer has detailed the pathophysiologic consequences of
hypoglycemia defined at this threshold [25]. Moreover,
two recent observational cohort studies have demon-
strated an independent association of mild hypoglycemia
with mortality [17,18]. Consequently, we hypothesized
that hypoglycemia would impact the magnitude of
resource utilization, reflected by ICU LOS.
We have the unique opportunity to analyze a large
diverse group of critically ill patients in this interna-
tional collaboration; the 3 datasets include a large sin-
gle-center cohort from an ICU in the United States
(Stamford Hospital), 3 ICUs from The Netherlands, and
21 ICUs from Western Europe and Israel that partici-
pated in the GLUCONTROL trial, a multicenter rando-
mized controlled trial of intensive insulin therapy [8].
Methods
Settings, patients, glycemic control programs and data
accrual
The Stamford cohort. Stamford Hospital is a 305-bed,
university-affiliated hospital. The 16-bed adult ICU
treats a heterogeneous population of medical, surgical,
and trauma patients. Medical and surgical house staff,
closely supervised by a team of intensivists, delivers
c a r e .T h ep a t i e n tc o h o r ti nS t a m f o r d( S T )i n c l u d e s
3,263 patients admitted to the ICU between January 12,
2007 and April 30, 2010 who had at least three blood
glucose values obtained during their ICU stay. Forty-one
patients admitted during this period with a diagnosis of
diabetic ketoacidosis or hyperosmolar nonketotic coma
were excluded from the study. The glycemic target dur-
ing the period of the investigation was 80-125 mg/dL.
Details of the protocol have been published previously
[26]. Most of the BG measurements (85%) were made
using bedside glucometers (AccuChek Inform, Indiana-
polis, IN) and capillary or venous blood; the remainder
were performed in the central laboratory using a using a
Siemens Advia 1800 analyzer (Siemens Medical
Solutions, Malvern, PA) or in the ICU using a
GEM4000 point of care analyzer (Instrument Labora-
tory, Lexington, MA). Data were abstracted from the
ICU’s comprehensive clinical database. Diabetic status
was determined prospectively based on all available clin-
ical information at the time of ICU admission.
The Dutch cohort. The three hospitals in The Nether-
lands are university-affiliated hospitals, with 700 beds
(Gelre Hospital, Apeldoorn, The Netherlands), 633 beds
(Tergooi Hospitals, Hilversum, The Netherlands), and
785 beds (Medical Center Haaglanden, The Hague, The
Netherlands). The 10-bed, 9-bed, and 18-bed adult ICUs
treat a heterogeneous population of medical, surgical,
and trauma patients. A team of intensivists delivers care
in a closed-format setting. The patient cohort in The
Netherlands (NL) includes 2,063 patients admitted to
the ICU between January 1, 2007 and December 29,
2009, who had at least three blood glucose values
obtained during their ICU stay: 1,098 patients (NL-L)
admitted between January 1, 2007 and January 31, 2008
were subjected to a “loose” intensive insulin therapy
guideline, and 965 patients (NL-S) admitted between
February 1, 2008 and December 29, 2009 were subjected
to a “strict” intensive insulin therapy guideline (see
below for details on “loose” and “strict” glucose control).
Per protocol, patients admitted during this period with a
diagnosis of diabetic ketoacidosis or hyperosmolar non-
ketotic coma were not subjected to treatment according
to the guideline. Loose intensive insulin therapy: blood
glucose control in the three participating ICUs followed
the 2004 Surviving Sepsis Campaign Guidelines [27,28]
and aimed for a BG < 150 mg/dl. Insulin dose and route
of administration (intravenous or subcutaneous) and
timing and type of blood glucose measurement (using
capillary or arterial blood, at the bedside or in a central
laboratory) were loosely defined in the guidelines in use.
ICUs nurses practiced blood glucose control. Strict
intensive insulin therapy: blood glucose control in the
three participating ICUs aimed for a BG between 80-
110 mg/dl; administration of insulin was intravenous at
all times, and BG measurements were performed at the
bedside. Blood glucose control required a high level of
intuitive decision-making. All BG measurements were
made by using bedside glucometers (AccuChek Inform;
Roche, Almere, The Netherlands) and arterial blood.
Details of the protocol have been published previously
[18]. Data were abstracted from the National Intensive
Care Evaluation (NICE) database, created daily by the
responsible intensivists (PES, FvBH, JPvdS) and main-
tained by the NICE Foundation [29].
The GLUCONTROL cohort. This cohort included
data from patients enrolled in the GLUCONTROL trial
[8] in 1 of the 21 units from 19 different hospitals in 7
different countries of Western Europe and Israel,
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number of ICU beds of the participating units ranged
from 5 to 44 (median, 12). Patients were randomized to
an intensive insulin therapy (target BG: 80-110 mg/dl)
(GL-IIT) or to a control arm (GL-C) with an intermedi-
ate glucose target (140-180 mg/dl), using an insulin pro-
tocol. BG checks were performed on arterial or central
venous samples when a catheter was in place and a
blood gas analyzer was preferentially used. Capillary
samples and a specific glucometer (Accu-Check Inform,
Roche Diagnostics, Mannheim, Germany) were allowed.
The data from the 914 patients with at least three BG
checks and survivor status were analyzed; the other 164
patients were evenly distributed between the GL-IIT
and GL-C groups (n = 82 in each arm).
Additional details about the glycemic control proto-
cols used in the three cohorts can be found in a recent
publication [18].
Statistical analysis
Continuous data are presented as mean (standard devia-
tion) or median (interquartile range), as appropriate,
a n dc o m p a r e db yu s i n gS t u d e n t ’s t test or the Mann-
Whitney rank-sum test, respectively. Categorical data
are presented as percentages and compared using the
Chi-square test. Multivariate analysis to assess the inde-
pendent association of any hypoglycemia (BG < 70 mg/
dL), as well as BG < 50 mg/dL and 50-69 mg/dL, with
ICU LOS included the following parameters found to be
statistically significant at P < 0.1 on univariate analysis:
age, modified APACHE II score (age component deleted
to avoid colinearity with age in the multivariate analysis:
age 45-54, 2 points; age 55-64, 3 points; age 65-74, 5
points; age ≥ 75, 6 points), medical diagnostic category
on admission to the ICU and mechanical ventilation.
The same model was used to assess independent contri-
butors to the risk of prolonged ICU stay, defined as
greater than the 75
th percentile for each cohort (3.1, 6.6,
and 12.8 days for the ST, NL, and GL cohorts, respec-
tively). Diabetes was not associated with mortality on
univariate analysis and therefore was not entered into
the multivariate model.
Mortality is defined throughout as hospital, not ICU,
mortality. Statistical analysis was performed using the
MedCalc statistical package version 10.1.1.6.0 http://
www.medcalc.be.
Results
Characteristics of the patients
In brief, age (all five subpopulations) and diabetic status
(data not available for NL cohorts) were similar. The
percentage of patients with nonsurgical admitting diag-
noses ranged from 39.9% (GL-C) to 64.1% (NL-L).
Mean (SD) APACHE II scores ranged from 16.0 (9.0)
(ST) to 19.7 (8.2) (NL-L), and mortality ranged from
14.2% (ST) to 27.5% (NL-L).
Significant differences in glycemic control also were
noted [16]. The median (IQR) number of BG measure-
ments per day ranged from 5.1 (3.6-7.6) (NL-L) to 9.3
(8.0-11.3) (ST). Mean BG (median, [IQR]) ranged from
117.9 (107.0-137.0) (NL-S) to 146.3 (128.1-164.6) (GL-
C) and coefficient of variation (CV, %) (median [IQR])
from 21.0 (14.8-28.5) (ST) to 31.8 (23.8-40.8) (NL-S).
Finally, the percentage of patients who experienced at
least one episode of hypoglycemia (BG < 70 mg/dL) ran-
ged from 17.8% (GL-C) to 64.9% (NL-S)
Comparison of patients with and without hypoglycemia
Table 1 demonstrates differences between patients with
hypoglycemia, including patients with minimum BG <
70 mg/dL, 50-69 mg/dL, and < 50 mg/dL, and those
without hypoglycemia for the entire cohort of 6,240
patients. Patients with hypoglycemia were older, more
likely to be admitted to the ICU with a nonsurgical
diagnosis, and more likely to be diabetic. They had
higher APACHE II scores and higher mortality. Addi-
tional differences included lower mean BG concentra-
tions and higher CV.
Figure 1 illustrates the negative correlation between
minimum BG during ICU stay and ICU LOS for the dif-
ferent cohorts (P for trend < 0.0001 for each of the
cohorts).
Multivariate analysis of factors associated with ICU LOS
Table 2 demonstrates that hypoglycemia–minimum BG
< 50 mg/dL as well as minimum BG 50-69 mg/dL–is
independently associated with prolonged ICU LOS,
defined as greater than the 75
th percentile for each
cohort (3.1, 6.6, and 12.8 days, respectively, for ST, NL,
and GL).
Association between ICU LOS and hypoglycemia,
stratified by severity of illness survivor status
Figure 2 illustrates that the difference in ICU LOS com-
paring patients with hypoglycemia and patients without
hypoglycemia is found across different ranges of severity
of illness, reflected by admission APACHE II score. Fig-
ure 3 stratifies this relationship by survivor status.
Dose response relationship between hypoglycemia and
ICU LOS
Figures 4a and 4b illustrate that most hypoglycemic
events occurred soon after ICU admission for patients
in the ST and NL cohorts. Of the patients with hypogly-
cemia in the ST cohort, 47% cohort had an episode
within the first 48 hours of ICU admission; in the NL
cohort, 72% of the patients with hypoglycemia in the
NL cohort had an episode within the first 48 hours of
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between the number of episodes of hypoglycemia and
ICU LOS. For the entire cohort of 6,240 patients, ICU
LOS was 1.8 (1.0-3.3) days for those without hypoglyce-
mia (n = 3,917) and 3.0 (1.5-6.7) days for those with a
single episode of hypoglycemia (n = 774; P < 0.0001).
Discussion
Although emerging literature has documented the
strong association between hypoglycemia during acute
and critical illness and an increased risk of mortality
[9,11-18], this is the first investigation that has focused
explicitly on the association of hypoglycemia with ICU
LOS, the predominant driver of resource utilization in
this population. The salient finding of this investigation
is that patients sustaining even a single episode of BG <
70 mg/dL during ICU stay incurred substantially greater
LOS than did those without an episode of hypoglycemia:
1.8 (1.0-3.3) vs. 3.0 (1.5-6.7) days (p < 0.0001). This
observation was independent of survivor status or sever-
ity of illness, as reflected by admission APACHE II
score. The relationship between ICU LOS and
Table 1 Comparison of patients with hypoglycemia to those without hypoglycemia
Minimum BG < 70 mg/dL Minimum BG 50-69 mg/dL Minimum BG < 50 mg/dL Minimum BG ≥ 70 mg/dL
Number 2,313 1,424 889 3,927
Age (yr) 70 (57-79) 70 (59-80) 69 (58-78) 66 (52-78)
DM (%)* 27.3 28.3 26.8 17.5
MED patient (%) 56.2 56.0 56.6 54.7
ICU LOS 5 (2.2-10.5) 4.2 (2-9) 6 (2.8-12.2) 1.8 (1.0-3.3)
APACHE II 20.8 (8.4) 19.9 (8.1) 22.2 (8.8) 15.2 (8.1)
Mortality (%) 29.6 26.5 34.6 13.1
Glucose control
BG per patient 45 (21-97) 36 (18-78) 65 (29-127) 11 (7-24)
BG per day 9.5 (7.2-11.9) 9.2 (6.6-11.2) 10.2 (8.1-12.5) 8 (5-10)
Mean (mg/dL) 118.3 (108.1-132.5) 120.0 (109.3-133.4) 116.5 (106.5-129.4) 128.1 (115.3-144.4)
CV (%) 31.6 (25.0-40.0) 29.0 (23.1-37.4) 35.0 (29-43.7) 19.2 (13.7-26.1)
*Includes only patients from ST and GL cohorts. Data displayed as percentage, median (interquartile range), or mean (standard deviation). P values comparing
patients without hypoglycemia to those with minimum BG < 70 mg/dL < 0.0001, except for MED patient p = 0.2581. DM, diabetes mellitus; MED patient, medical
diagnosis on admission to the ICU, rather than surgical or trauma; BG, blood glucose; BG per patient, number of BG measurements per patient; BG per day,
number of BG measurements per day per patient; Mean, individual patient’s mean BG during ICU stay; CV, individual patient’s mean coefficient of variation
during ICU stay.
Figure 1 Relationship between minimum BG during ICU stay and ICU LOS: 3 cohorts.
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separate cohorts of patients. Finally, there was a dose
response relationship between hypoglycemia and
resource utilization: the number of discrete episodes of
hypoglycemia was directly and positively correlated with
ICU LOS.
The major interventional trials of IIT [4-8,10] as well
as large observational cohort studies [12,13,16,17]
describing the association of hypoglycemia with mortal-
ity do not detail differences in ICU LOS comparing
those who experienced hypoglycemia to those who did
not. However, the findings of the current investigation
corroborate the limited data available in the literature
that do address this topic. Arabi et al. analyzed severe
hypoglycemic events (BG < 40 mg/dL) that occurred in
their randomized, controlled trial of IIT [9]. ICU LOS
(median, IQR) was considerably longer in patients with
hypoglycemia than in those without: 5.8 (2.0-12.9) vs.
1.0 (0.8-1.9) (p value not supplied). Additionally, Vrie-
sendorp and colleagues performed an observational
cohort study of patients sustaining severe hypoglycemia
(BG < 45 mg/dL) [15]. Index cases and controls were
matched by the time of the hypoglycemic event. The
median (range) time in days from the index moment to
death or hospital discharge was longer in patients with
hypoglycemia: 11 (0-204) vs. 8 (0-146; p value not
provided).
The multicenter, international nature of the investiga-
tion increases the generalizability of the findings; the het-
erogeneous 6,240 patient cohort were admitted with
varying severities of illness and ICU LOS and treated in
ICUs using different glycemic targets, measurement tech-
nologies, and glycemic management protocols. One limita-
tion is the absence of data differentiating between
spontaneous and therapy-induced hypoglycemia; it is
unclear whether these may have the same association with
increased ICU LOS. The use of bedside glucometers for
measurement of capillary blood is an additional limitation
of this investigation, because this measurement technology
has been associated with analytic inaccuracies, especially
in the hypoglycemic range [30-32]. Notably, the retrospec-
tive nature of this investigation is an acknowledged weak-
ness. This was unavoidable, because it would be unethical
to perform a randomized, controlled trial of induced hypo-
glycemia in a population of critically ill patients. However,
while the design of the study precludes proof of causality,
Table 2 Multivariate analysis of factors independently
associated with prolonged ICU LOS
OR (95% CI) P value
Mechanical ventilation 3.82 (3.20-4.51) < 0.0001
Minimum BG < 70 mg/dL 2.50 (2.12-2.95) < 0.0001
Minimum BG 50-69 mg/dL 2.16 (1.81-2.59) < 0.0001
Minimum BG < 50 mg/dL 1.78 (1.39-2.29) < 0.0001
Medical diagnosis on admission 1.59 (1.34-1.88) < 0.0001
Modified APACHE II score 1.04 (1.03-1.06) < 0.0001
Age 1.00 (0.99-1.01) 0.6002
The 5 parameters in these multivariate models were each significant at p <
0.10 on univariate analysis. Diabetes was not significant on univariate analysis
and is therefore not included in the models. Prolonged ICU LOS is defined as
greater than the 75
th percentile for each cohort (3.1, 6.6, and 12.8 days for ST,
NL and GL respectively). OR per year for age and per point for Modified
APACHE II score.
Figure 2 Relationship between hypoglycemia and ICU LOS, stratified by APACHE II score.
Krinsley et al. Annals of Intensive Care 2011, 1:49
http://www.annalsofintensivecare.com/content/1/1/49
Page 5 of 9there are several lines of evidence that suggest strongly
that hypoglycemia led to increased resource utilization,
rather than was a consequence of more frequent BG mea-
surements in patients who required longer ICU stays.
Hypoglycemia occurred early in the course of ICU stay;
47% and 72% of the patients with hypoglycemia in the ST
and NL cohorts, respectively, experienced an episode
within the first 48 hours of ICU stay. Moreover, the rela-
tionship between hypoglycemia and increased LOS was
independent of severity of illness; patients with hypoglyce-
mia who had mild, moderate, or severe levels of illness,
reflected by APACHE II score sustained significantly
longer LOS than did those without hypoglycemia, and this
relationship was seen for survivors as well as nonsurvivors.
There are some possible links between hypoglycemia
and worsened outcome or complicated course of criti-
cal illness [25,33]. First, the physiological mechanisms
triggered by hypoglycemia are commonly impaired
during critical illness. These include the inhibition of
insulin release, typically occurring when BG is < 80
mg/dl, an increased release of glucagon, epinephrine,
and growth hormone when BG is < 65 mg/dl, and
increase release of cortisol when BG is < 55 mg/dl
[34]. During critical illness, exogenous insulin is
infused and the levels of glucagon, epinephrine, corti-
sol, and growth hormone are typically already elevated.
Second, large swings in BG, as observed when hypogly-
cemia is aggressively treated with a large amount of
intravenous glucose, are typically associated with
cellular damage [35]. Third, the detrimental effects of
hypoglycemia are well documented in the brain.
Indeed, glucose is the preferential energetic substrate
in the brain. The absence of cerebral stores of glucose
and the diffusive character of transport imply that the
glucose concentration in neurons and glial cells is
entirely determined by BG [35].
The main driver of the cost of care of patients
admitted to the ICU is length of stay [21,22,36]. This
investigation, demonstrating consistent evidence of
increased ICU LOS among critically ill patients sustain-
ing hypoglycemia compared with those without hypogly-
cemia, has important implications for the management
of these patients. Although this study must be consid-
ered hypothesis-generating, the evidence from this study
and other recent investigations strongly suggests that
avoidance of hypoglycemia has a beneficial effect not
only on survival, but on cost, an important goal in the
context of estimates that ICU care consumes 20-30% of
individual hospital’s resources and 0.5-1.0% of US Gross
National Product [19,20].
Conclusions
This multicenter investigation demonstrates a strong
association between mild hypoglycemia (BG < 70 mg/
dL) and increased ICU LOS, independent of severity of
illness and survivor status. Successful avoidance of hypo-
glycemia has the potential to significantly decrease the
cost of care of the critically ill.
Figure 3 Relationship between hypoglycemia and ICU LOS, stratified by survivor status.
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Figure 4 Timing of hypoglycemic events. (a) Timing of hypoglycemic events: Stamford cohort. (b) Timing of hypoglycemic events:
Netherlands cohort.
Figure 5 Relationship between number of episodes of hypoglycemia and ICU LOS: 3 cohorts.
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